Lyra Therapeutics (LYRA) Equity Ratio (2021 - 2025)
Lyra Therapeutics (LYRA) has disclosed Equity Ratio for 5 consecutive years, with 0.1 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio fell 137.82% to 0.1 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.1, a 137.82% decrease, with the full-year FY2024 number at 0.17, down 72.13% from a year prior.
- Equity Ratio was 0.1 for Q3 2025 at Lyra Therapeutics, down from 0.03 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.93 in Q1 2021 to a low of 0.1 in Q3 2025.
- A 5-year average of 0.52 and a median of 0.63 in 2023 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: skyrocketed 43.33% in 2023, then plummeted 137.82% in 2025.
- Lyra Therapeutics' Equity Ratio stood at 0.63 in 2021, then increased by 17.41% to 0.73 in 2022, then dropped by 14.61% to 0.63 in 2023, then tumbled by 72.13% to 0.17 in 2024, then tumbled by 156.66% to 0.1 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Equity Ratio are 0.1 (Q3 2025), 0.03 (Q2 2025), and 0.07 (Q1 2025).